PMC7767729_01
Whole-body PET-CT of primary lung cancer.
OTT-13-13143-g0001.jpg
PMC7767729_01_OTT-13-13143-g0001.jpg
f0001
After admission, the whole-body PET-CT showed intense uptake of the radiotracer fluorine-18 fluorodeoxyglucose by the left and right lungs, revealing multiple metastases (Figure 1A). In addition, hypermetabolic lesions were observed in the thyroid (Figure 1B), adrenal gland (Figure 1C), bone (Figure 1D) and left psoas (Figure 1E).
Cutaneous metastasis of lung adenocarcinoma. (A) Subcutaneous nodules in the chest and abdomen. Skin metastasis biopsy from the left chest wall shows poorly differentiated metastatic adenocarcinoma (H&E, original magnification x100 (B), x200 (C)). (D-F) Immunohistochemical staining shows positivity for, in order, CK7 (original magnification x200), TTF-1 (original magnification x200) and napsin A (original magnification x200), indicating that the metastasis is of lung origin.
OTT-13-13143-g0002.jpg
PMC7767729_01_OTT-13-13143-g0002.jpg
f0002
We took pictures of subcutaneous nodules in the chest and abdomen of the patient (Figure 2A). A (Figure 2B-F) and negative for CK20 and P63.
Imaging of lung cancer. (A) PET-CT indicates that the largest tissue mass is in the lower left lung. During treatment, additional CT scans were performed in (B) December 2019 and (C) March 2020.
OTT-13-13143-g0003.jpg
PMC7767729_01_OTT-13-13143-g0003.jpg
f0003
According to PET-CT, the largest tissue mass at the time of writing was approximately 2 cmx1.4 cmx1.7 cm, which was located in the lower left lung (Figure 3A), and multiple hilar lymph nodes and flocculent shadows remained scattered in the left and right lungs. December 2019 (Figure 3B) and March 2020 (Figure 3C). During the follow-up period, the patient developed fatigue and scattered rashes on his chest after taking the medicine for one month.